TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05194306
Drug: Perla® Cold Preservation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perla® must be cooled to 2° to 6 °C prior to use. The cold Preservation Solution is used to flush the isolated organ immediately before removal from the donor and/or immediately after removal from the donor. The solution is then left in the organ vasculature during hypothermic storage and transportation.
Study: NCT05107492
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: following a single subcutaneous dose of placebo
Study: NCT06143007
Drug: BB3008 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: BB3008 tablets will be administered orally once daily (QD).
Study: NCT04950920
Drug: Y-2 sublingual tablets
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg Edaravone+6mg d-borneo OR， Bid
Study: NCT05831644
Drug: C21
Normalized name: C18-C21 alkane
Approvals — FDA: no, EMA: no, PMDA: no
Description: C21 is an angiotensin II type 2 receptor agonist (ATRAG)
Study: NCT05545514
Drug: One out of 140 predefined homeopathic medical products (HMP) in potency C200 or C1000,
Approvals — FDA: no, EMA: no, PMDA: no
Description: To investigate the efficacy of individualised homeopathic treatment (potency C200 and/or C1000) in comparison to placebo regarding the number of UTI treated with antibiotic agents.
Study: NCT06509958
Drug: HR18034
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR18034
Study: NCT04984369
Drug: HLX208
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX208 450mg bid po OR 600mg bid po OR 900mg bid po
Study: NCT06651112
Drug: Antipsychotic drugs
Normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any Antipsychotic drugs prescripbe as standrd of care for this specific populaton
Study: NCT00036140
Drug: Investigational drug
Normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04699110
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control group will receive adenosine (100 to 400 mcg)
Study: NCT06620731
Drug: FCN-437c capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 200 mg of FCN-437c capsules with approximately 240 mL of warm water in the morning on an empty stomach.
Study: NCT06684366
Drug: Statins (atorvastatin or simvastatin)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A resting transthoracic echocardiogram Non-invasive functional imaging for myocardial ischemia or coronary computed tomography angiography (CCTA) is recommended as the initial test for diagnosing CAD in symptomatic patients in whom obstructive CAD cannot be excluded by clinical assessment alone
Study: NCT05532852
Drug: standard-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard-of-care
Study: NCT06500819
Drug: B7-H3CART Dose (Intravenous)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level -1 (DL-1) 0.3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 1 (DL1) 1 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 2 (DL2) 3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 2 (DL2) 3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 3 (DL3) 9 x 106 transduced T cells/kg
Study: NCT05445232
Drug: LY3437943
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05445232
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05076032
Drug: OXO-001
Normalized name: 7-oxo-prasterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXO-001 oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks approximately.
Study: NCT05076032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks, approximately.
Study: NCT05922761
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Semi-synthetic macrolide antibiotic, taken orally
Study: NCT06457074
Drug: Spironolactone Oral Tablet
Normalized name: spironolactone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will be started spironolactone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).
Study: NCT06137742
Drug: Placebo for PF-07868489
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06263998
Drug: NCP112 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT06666270
Drug: SYN818
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will orally receive SYN818
Study: NCT05620472
Drug: Diagnostic Test: whole body study and SPECT with [99mTc]Tc(CO)3-(HE)3-Ec1
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single intravenous injection of \[99mTc\]Tc(CO)3-(HE)3-Ec1, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
Study: NCT04429555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg (5 matching capsules) twice daily for 7 days
Study: NCT06261905
Drug: [11C]-PHNO
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHNO is used as a tracer for in-vivo imaging.
Study: NCT05286996
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - local anaesthesia
Study: NCT04666259
Drug: ABL001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asciminib will be supplied as 20 mg or 40 mg strength tablets will be administered orally in accordance with the assigned cohort.
Study: NCT04979780
Drug: Low molecular weight heparin (LMWH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrospective cohort analysis using US Optum De-Identified EHR data. LMWH (dalteparin, enoxaparin, tinzaparin)
Study: NCT04979780
Drug: Direct Oral Anticoagulants (DOAC)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrospective cohort analysis using US Optum De-Identified EHR data. DOAC (apixaban, dabigatran, edoxaban, rivaroxaban).
Study: NCT05004350
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of:~irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous infusion, and 5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion
Study: NCT05534919
Drug: Nefecon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefecon is taken orally as capsules once daily for 9 months.
Study: NCT06239532
Drug: HAIC+TAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procedure: HAIC+TAE After successful percutaneous hepatic artery cannulation for continuous pumping of drugs. Oxaliplatin(85 mg/m2); Raltitrexed (3 mg/m2) ，continuous infusion for 3 hours. HAIC was performed at an interval of at least 21 days.
Study: NCT05717049
Drug: Theophylline Tablets
Normalized name: Theophylline Tablets
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 week oral treatment
Study: NCT05631093
Drug: DOR/ISL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 100 mg doravirine (DOR) with 0.25 mg Islatravir (ISL) in tablet form, taken orally, once daily.
Study: NCT06231316
Drug: Norepinephrine Injection
Normalized name: norepinephrine Injection
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine is both a neurotransmitter and a hormone. It is essential vasopressor for rapid blood pressure support, crucial in maintaining hemodynamic stability
Study: NCT06683040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride
Study: NCT06388616
Drug: Balcinrenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg, Immediate release capsule to be taken orally.
Study: NCT06457191
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will ingest either a placebo or roflumilast 500mg in a single blind crossover study and receive transcranial magnetic stimulation to the primary motor cortex.
Study: NCT05278546
Drug: ILB2109
Approvals — FDA: no, EMA: no, PMDA: no
Description: ILB2109 tablets by mouth once per day at dosages prespecified by the protocol. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
Study: NCT04990388
Drug: Antipyretic
Normalized name: ANTIPYRETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants will receive oral premedication prior to infusion
Study: NCT05113771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06122012
Drug: HSK16149 20mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK16149 20mg BID with L-carnitine hydrochloride tablets 2 tablets TID ；Lipoic acid tablets 2 tablets BID with L-carnitine hydrochloride tablets 2 tablets TID；
Study: NCT04984226
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo and filler for for sodium bicarbonate capsules will be comprised of microcrystalline cellulose. Capsule appearance for control and sodium bicarbonate will be the same.
Study: NCT05700084
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals. It is administered continuously for 14 days from day 1 to day 14, with a 21 day treatment cycle.
Study: NCT06318988
Drug: Daflon
Normalized name: Daflonex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venoactive drugs
Study: NCT05929677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive placebo (saline) intravenously. They will also have the opportunity to self-administer saline during the 60-minute free-access IV self-administration period in session 3.
Study: NCT04237103
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral capsules taken once a week
Study: NCT04237103
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered identically to the experimental group
Study: NCT05137600
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin is a sensitive P-gp index inhibitor to evaluate potential effect of P-gp inhibition on ATI-2173 and its metabolites(clarithromycin)
Study: NCT04675450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
Study: NCT06193811
Drug: Avenciguat (BI 685509) (intended commercial formulation (iCF))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avenciguat (BI 685509) (intended commercial formulation (iCF))
Study: NCT06193811
Drug: Avenciguat (BI 685509) (trial formulation 2 (TF2))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avenciguat (BI 685509) (trial formulation 2 (TF2))
Study: NCT06094283
Drug: YCT-529
Normalized name: YCT-529
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose (planned doses of 10, 30, 90 and 200 mg; dose levels will not exceed 250 mg
Study: NCT06094283
Drug: YCT-529 Placebo
Normalized name: YCT-529
Approvals — FDA: no, EMA: no, PMDA: no
Description: YCT-529 Placebo
Study: NCT06580366
Drug: Sennosid A+B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel Preparation
Study: NCT06580366
Drug: Sodium Picosulfate/Magnesium Oxide/Citric Acid
Normalized name: sodium picosulfate/magnesium oxide/citric acid 10 mg-3.5 gram-12 gram ORAL POWDER IN PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel Preparation
Study: NCT05832502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline control) administered intramuscularly by injecting 0.5 mL into the deltoid muscle
Study: NCT05940376
Drug: rapid acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical insulin drops were prepared by diluting 1 unit of fast-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops were preserved at low temperature (2°C) and, was provided by the cornea specialist and was self-administered by patients at a dosage of 1 eye drop 4 times daily. Treatment continued until NK healed and then tapered accordingly. Patients would discontinue topical insulin if the condition did not improve or worsen within 4 weeks. Patients were followed up daily and slit-lamp photographs were captured with and without fluorescein corneal staining.
Study: NCT05670795
Drug: Recombinant Follicle Stimulating Hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: clinical pregnancy rates
Study: NCT05670795
Drug: Recombinant Follicle Stimulating Hormone and Clomiphene Citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: clinical pregnancy rates
Study: NCT04843787
Drug: SLV213
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLV213 oral capsule (200mg) BID
Study: NCT04843787
Drug: SLV213
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLV213 oral capsule (400mg) BID
Study: NCT04843787
Drug: SLV213
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLV213 oral capsule (800mg) QD
Study: NCT04843787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule (200mg) BID
Study: NCT04843787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule (400mg) BID
Study: NCT06194851
Drug: Saline nasal spray
Normalized name: Saline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veteran participants will self-administer 40 IU of the placebo (intranasal saline spray) 30 minutes before the start of each bCBCT session.
Study: NCT04843787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule (800mg) QD
Study: NCT05887258
Drug: Opioid free anesthesia
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: It administers a combination of drugs to replace the opioid derivatives. Among them, we will use lidocaine, ketamine, dexmetomidine, and magnesium sulfate in continuous infusion adjusted to the patient's weight during surgery.
Study: NCT05887258
Drug: Opioid based Anesthesia
Normalized name: Opioid anesthetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: administer anesthesia based on opioids such as fentanyl and/or morphine to guarantee analgesia during the surgical intervention.
Study: NCT04956328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04787198
Drug: hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and 30 the volume of the bolus will be 0.2 mL .
Study: NCT04787198
Drug: isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of 0.2 mL isotonic saline (9 mg/mL) will be administered to the FDI muscle as control.
Study: NCT05245578
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.
Study: NCT06144710
Drug: SG301 SC Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection every two weeks
Study: NCT06355258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
Study: NCT06355258
Drug: placebo + low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU LMWH once a day + Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
Study: NCT06355258
Drug: troxerutin + low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU LMWH once a day + Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
Study: NCT05279235
Drug: JT001 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days
Study: NCT06215989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one tablet once daily will be given on the basis of standard treatment of ACS recommended by guidelines
Study: NCT04977336
Drug: HB/APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration.
Study: NCT05898984
Drug: Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve).
Study: NCT06058442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-15 capsules of placebo per day - over 6 months
Study: NCT06239194
Drug: MDX2001
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDX2001 intravenous infusion
Study: NCT05193916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: no active drug contained
Study: NCT04715542
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered with subcutaneous injections 3 times a week at 1 ampoule at 1 mL during the chemotherapy and shall be continued during 6 weeks after the end of chemotherapy . The first injection will be administered on the day of the first dose of chemotherapy, before the injection of the first dose of chemotherapy.
Study: NCT06128044
Drug: CB-012
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB-012 allogeneic CAR-T cell therapy targeting CLL-1 Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion
Study: NCT06176599
Drug: Shenxiao Yuning decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus 30g, Radix Pseudostellariae 15g, Rehmannia glutinosa 15g, Rhodiola rosea 12g，Cimicifuga 15g，Cuttlebone 15g，Poria 15g，Cicada degeneration 9g，Rheum palmatum 6g.
Study: NCT06176599
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: (i) Diabetes education: all study participants were given dietary guidance for diabetic nephropathy, low-fat, high-quality, low-protein diet, and restricted sodium intake; maintain emotional stability, quit smoking and alcohol, and exercise appropriately; (ii) control of blood glucose: all study participants routinely received hypoglycaemic treatment, hypoglycaemic measures are not limited (including oral hypoglycaemic drugs or insulin injection); (iii) Control of lipids: study participants with substandard lipids routinely receive lipid-lowering treatment; (iv) Control of blood pressure: those with blood pressure \&gt;140/90 mmHg should be treated with antihypertensive drugs to control blood pressure, and antihypertensive measures are not limited (CCB class, ACEI or ARB class, α, β-blockers, diuretics, etc.); ⑤ Other symptomatic treatment.
Study: NCT05615363
Drug: OPC 131461 10mg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-131461 5 mg tablet x 2，once-daily oral administration for 14 days
Study: NCT05615363
Drug: OPC 131461 5mg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-131461 5 mg tablet and placebo tablet，once-daily oral administration for 14 days
Study: NCT05615363
Drug: OPC 131461 2mg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-131461 1 mg tablet x 2，once-daily oral administration for 14 days
Study: NCT05615363
Drug: OPC 131461 1mg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-131461 1 mg tablet and placebo tablet，once-daily oral administration for 14 days
Study: NCT05615363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet，once-daily oral administration for 14 days
Study: NCT05754762
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Advanced intravenous injection of remifentanil before the etomidate injection
Study: NCT06667934
Drug: Zuoqing powder was dissolved in 100ml normal saline, retained enema, once a night
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zuoqing powder was dissolved in 100ml normal saline, retained enema, once a night
Study: NCT05110794
Drug: LY3502970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Orally.
Study: NCT05862402
Drug: Dose-adjustment by PKPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-adjustment by pharmacokinetic and pharmacodynamic using Monte Carlo simulation
Study: NCT06682130
Drug: Group A：Patients with PR or ctDNA positivity after salvage treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Immunotargeted therapy~   * Ottuzumab introvenous infusion, 1000mg day1;~  * Glofitamab introvenous infusion Group A: 2.5mg day8~2. Autologous stem cell transplantation SEAM regimen~   * Simustine 250mg/m2 orally, day1~  * Etoposide 200mg/m2 intravenous infusion, day2-5~  * Cytarabine 400mg/m2 intravenous infusion, day2-5~  * Metformin 140mg/m2 intravenous infusion, day6; Patients in Group A who intend to receive Glofitamab+ASCT will receive Glofitamab 2.5mg on day8 and start ASCT pretreatment on day15.